Healthcare Sales & Marketing Network News: ranolazine

Searching News Database: ranolazine

HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jan 2012
New FDA Approved Labeling For VYTORIN(R) (Ezetimibe/Simvastatin) Includes Results From the Study of Heart and Renal Protection (SHARP) in Patients With Moderate to Severe Chronic Kidney Disease
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 12 Mar 2009
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 27 Feb 2009
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 28 Jan 2009
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 6 Nov 2008
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 14 Aug 2008
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 24 Apr 2008
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 15 Apr 2008
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2008
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 Mar 2008
Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Biopharmaceuticals Cardiology

HSMN NewsFeed - 4 Feb 2008
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Devices Licensing

HSMN NewsFeed - 18 Dec 2007
FDA Approves New Mechanism of Action Labeling for Ranexa(R)
Biopharmaceuticals. Cardiology FDA

HSMN NewsFeed - 7 Dec 2007
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Nov 2007
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Biopharmaceuticals Cardiology Endocrinology

HSMN NewsFeed - 5 Nov 2007
Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Biopharmaceuticals Cardiology

HSMN NewsFeed - 27 Sep 2007
CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 15 Aug 2007
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 14 Aug 2007
CV Therapeutics Launches 1000 mg Ranexa(R) Tablet
Biopharmaceuticals Cardiology

HSMN NewsFeed - 16 Jul 2007
CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 24 May 2007
CV Therapeutics Significantly Reduces Operating Expenses
Biopharmaceuticals

HSMN NewsFeed - 14 May 2007
CV Therapeutics Submits New Drug Application For Regadenoson
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Apr 2007
Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology

HSMN NewsFeed - 14 Mar 2007
JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Mar 2007
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Dec 2006
CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 4 Dec 2006
Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial
Biopharmaceuticals Cardiology

HSMN NewsFeed - 26 Oct 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology

HSMN NewsFeed - 11 Oct 2006
CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
Biopharmaceuticals

HSMN NewsFeed - 5 Oct 2006
CV Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office and European Patent Office for Drug-Eluting Stent Technology
Devices Interventional Cardiology

HSMN NewsFeed - 26 Sep 2006
CV Therapeutics Completes MERLIN TIMI-36 Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 7 Jul 2006
CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as Planned Based on Final Scheduled DSMB Meeting
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Jun 2006
CV Therapeutics Acquires Rights to Ranolazine in Asia
Biopharmaceuticals Licensing

HSMN NewsFeed - 9 May 2006
Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
Biopharmaceuticals Cardiology

Return to NewsFeed

Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 23 additional stories matching:
ranolazine
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.